Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

This study has been completed.
Sponsor:
Collaborator:
Elan Pharmaceuticals
Information provided by (Responsible Party):
Biogen
ClinicalTrials.gov Identifier:
NCT00055536
First received: March 4, 2003
Last updated: June 14, 2016
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2003
  Primary Completion Date: July 2003 (Final data collection date for primary outcome measure)